Hybrid prokaryotic-eukaryotic vectors for targeted gene delivery to brain tumours in animal models

我们的目标是开发一种治疗人脑胶质母细胞瘤的新策略。这些脑瘤是最致命的恶性肿瘤之一。尽管在神经外科、放射和化疗方面取得了进展，但在这些肿瘤的治疗方面却进展甚微。因此，迫切需要新的治疗策略。基因治疗是一种有吸引力的癌症治疗方法。胶质母细胞瘤是癌症基因治疗最早的靶点之一，但由于向肿瘤中输送治疗基因的效率低下，第一批临床试验并不成功。因此，有必要开发新的载体系统，该系统是安全的，并能够在肿瘤内提供强大的治疗性基因表达。为了实现这两个目标，这些载体需要针对肿瘤组织。我们最近发现，各种病毒的属性相结合导致了用于高效和靶向系统基因治疗的混合病毒载体的产生。我们将利用这一策略产生一种新型的混合载体，用于向胶质母细胞瘤靶向输送治疗性基因。这些方法可能导致靶向载体系统的产生，这将代表着人类胶质母细胞瘤治疗和治疗的重大进步。

We aim to develop a novel strategy for the treatment of human glioblastomas. These brain tumours are one of the most lethal malignancies. Despite progress in neurosurgery, radiation and chemotherapy, little progress has been made in the treatment of these tumours. Therefore, new therapeutic strategies are urgently needed.Gene therapy is an attractive approach for cancer treatment. Glioblastomas were one of the earliest targets of cancer gene therapy, but the first clinical trials were not successful because of the inefficient delivery of therapeutic genes into the tumours. Thus, there is a need to develop new vector systems that are safe and able to provide strong expression of the therapeutic genes within the tumours. To achieve these two goals, these vectors need to be specifically targeted to the tumour tissue.We have recently showed that combination of attributes of various viruses resulted in the generation of hybrid viral vectors for efficient and targeted systemic gene therapy. We will use this strategy to generate a novel hybrid vector for targeted delivery of therapeutic genes to glioblastoma.These approaches could result in the derivation of a targeted vector system which would represent a major advance in the management and therapy of human glioblastoma.